Abstract. Inflammatory bowel disease (IBD) is a spectrum of immune-mediated chronic disorders of the intestine. Patients with IBD tend to exhibit significantly elevated levels of IgE in their serum. In general, the pathogenesis of IBD exhibits inflammatory events such as immunoglobulin E (IgE)-mediated hypersensitivity. We examined the effect of the non-anaphylactogenic anti-IgE antibody, which has been known to block IgE functions, in an animal model of ulcerative colitis induced by the oral intake of dextran sulfate sodium (DSS) for seven days. The non-anaphylactogenic anti-IgE antibody was subcutaneously injected on day 0 of DSS treatment. The disease activity index (DAI) was calculated by scoring intestinal states, including body weight loss, diarrhea, and rectal bleeding, and the activities of myeloperoxidase (MPO) and chymase were measured in the colon tissue. In addition, the expression of tumor necrosis factor (TNF)-· and cyclooxygenase (COX)-2 was determined by Western blotting. Administration of the anti-IgE antibody markedly reduced the histological damage to the colon and the DAI increment exhibited by the DSS-induced colitis. The anti-IgE antibody also significantly suppressed the activities of MPO and chymase as well as the expression of TNF-· and COX-2 in the DSS-treated colon tissue. Furthermore, the elevation of IgE levels in serum was induced by DSS and reduced by anti-IgE antibody injection. Thus, these results indicate that the IgE response played an important role in the clinical signs and the expression of inflammatory mediators in a colitis model caused by DSS treatment, suggesting that the non-anaphylactogenic anti-IgE antibody may be a useful therapeutic agent for ulcerative colitis.
Introduction
Inflammatory bowel disease (IBD) is a spectrum of immunemediated chronic gastrointestinal disorders, including ulcerative colitis (UC) and Crohn's disease (CD). The pathogenesis of IBD is believed to result from the interaction of genetic, immune, and environmental factors (1) (2) (3) . UC and CD are associated with intestinal and extra-intestinal manifestations, which comprise weight loss, diarrhea accompanied with blood and mucus, fever, gastric dysmotility, and shortening of the colon (4) . UC exhibits a pathological state primarily affecting the superficial layer of the colon mucosa, and the histological analysis of UC patient tissue shows general features, such as ulceration of the mucosa, blunting and loss of crypts, and infiltration of inflammatory cells (5) . However, the pathogenesis of UC is unknown. Disruption of immune systems in the intestinal tract has been suggested to be involved in the etiology of UC. Prolonged and chronic UC may progress to colorectal cancer (6) . The conventional treatment of IBD includes aminosalicylates, corticosteroids, and immunosuppressive drugs. However, they have a slow onset of action and many patients do not respond to long-term use. For the treatment of IBD, current studies are thus focusing on the development of new biological therapies, selectively blocking the inflammatory cascade with new drugs such as immunomodulating agents and antiinflammatory cytokines (7, 8) .
Immunoglobulin E (IgE) is known to play an important role in inflammatory reactions. A complex of IgE and specific antigen causes the activation of mast cells through crosslinking to high affinity IgE receptor. IgE-mediated mast cell degranulation is involved not only in immediate hypersensitivity but also in the elicitation of delayed-type hypersensitivity including IBD, which is characterized by T cell-driven inflammatory cell infiltration. In the gastro-intestinal tract, an increased number of mast cells were observed in patients with UC and CD (9) . Mast cell-derived mediators, such as tryptase and TNF-·, secreted by mast cell activation were significantly elevated in UC tissue (10, 11) . In a previous study, we also observed that tryptase-positive mast cells expressed protease-activated receptor (PAR) and TNF-· in UC patient tissues (12) . Interestingly, most IBD patients, particularly with UC, showed prevalent allergic symptoms and high serum IgE levels (13) . Moreover, an IgE response in the intestine was observed during infection with T. spiralis, H. polygyrus and Strongyloides venezuelensis in rats (14) . These studies indicate that IgE-dependent mechanisms may be involved in the pathogenesis of IBD as well as the protective immunity that develops against individual gastrointestinal nematodes.
Recently, therapeutic anti-IgE antibodies have been developed to reduce free IgE levels and to block the binding of IgE to FcεRI without crosslinking IgE and subsequently triggering degranulation of IgE-sensitized cells. The nonanaphylactogenic anti-IgE monoclonal antibody is able to bind the specific site of IgE recognizing IgE receptors, FcεRI and FcεRII. It presumably recognizes an epitope within the FcεRI-binding region of IgE and does not induce degranulation in IgE-sensitized mast cells. As a result of this binding specificity, the antibody was termed the nonanaphylactogenic antibody (15, 16) . These antibodies inhibit the functions of IgE-effector cells by blocking IgE binding to IgE receptors without cell activation because it cannot bind to IgE on cell surfaces where the FcεRI receptor has already masked the anti-IgE epitope.
Dextran sodium sulfate (DSS)-induced colitis in mice described by Okayasu et al has a phenotype similar to human acute and chronic UC (17) . Tissue injury in DSS-induced colitis is associated with histological changes including crypt shortening, progressing to crypt dropout, patchy mucosal inflammation, and erosion of the epithelium (1) . In the present study, we evaluated the potential use of a non-anaphylactogenic anti-IgE antibody as a new therapeutic drug for the treatment of IBD, particularly UC. Using an animal model of DSS-induced colitis, we examined the involvement of IgE response and the inhibitory effects of non-anaphylactogenic anti-IgE antibody in the pathogenesis of colitis.
Materials and methods

Animals and reagents.
Female BALB/c mice (7 weeks old) were obtained from the SamTaco animal facility (Gyeonggi, Korea). Mice were housed in a specific pathogen-free environment for at least 1 week for adaptation to the environmental changes and were sacrificed by CO 2 inhalation at the end of the study. DSS (mol wt; 36,000-50,000) was purchased from ICN Biomedicals (Aurora, OH). Purified anti-mouse IgE mAb (R35-92) and control IgG1 were from BD-Pharmingen (San Diego, CA). The specific antibodies against TNF-· and COX-2 were from Santa Cruz Biotechnology (Santa Cruz, CA). All chemical reagents were from Sigma Co. (St. Louis, MO).
Induction of colitis by DSS. Acute colitis in mice was induced by providing drinking water ad libitum containing 5% (w/v) DSS for 7 days. Mice were checked daily for loss of body weight, stool consistency and the presence of gross bleeding. Mice were randomized into groups receiving anti-IgE antibody (5 μg/kg or 50 μg/kg), rat control IgG (50 μg/kg), or saline as a negative control. Antibodies diluted with saline (50 μl) were subcutaneously injected only once on day 0 of DSS treatment. Mice finally were sacrificed and assessed after DSS treatment for 7 days.
Disease activity index (DAI).
The disease activity index (DAI) was derived by scoring three major clinical signs, which were weight loss, diarrhea, and rectal bleeding, 7 days after DSS administration as described by Murthy et al (18) . Loss of body weight was calculated as the difference between the initial and actual weight. Diarrhea was showed as mucus/fecal material adherent to anal fur. The presence or absence of diarrhea was confirmed by examination of the colon following completion of the experiment. Mice were sacrificed and the colons were excised from the animals. Diarrhea was defined by the absence of fecal pellet formation in the colon and the presence of continuous fluid fecal material in the colon. Rectal bleeding was defined as diarrhea containing visible blood and gross rectal bleeding and scored as described for diarrhea.
Three major clinical signs (weight loss, diarrhea, and occult/gross bleeding) were scored separately as shown in Table I . The DAI was calculated from the score of the clinical signs using the following formula: DAI=(weight loss score) +(diarrhea score)+(rectal bleeding score). The clinical parameters used here are comprehensive functional measures that are analogous to the subjective clinical symptoms observed in human ulcerative colitis. This method of scoring has been validated by repeated studies. It correlates well with histological healing measured as crypt scores. A significant decrease in the DAI ( * p<0.05) is considered an end-point of successful therapy.
Histochemical staining. The distal colons were removed immediately from the mice after euthanasia. The length of colon was measured and the feces were carefully removed from the GI tract lumen. Colon tissue was fixed in 4% buffered paraformaldehyde (pH 7.0), embedded in paraffin, and sectioned (6-μm) onto gelatin-coated glass slides. After deparaffinization with xylene and rehydration through gradual ethanol washes (100%, 90%, 80%, 70%, and 0%), sections were stained with hematoxylin and eosin (H&E). All specimens were visualized and photographed under a microscope using a camera system (Olympus LK2, Japan).
Myeloperoxidase activity assay. Myeloperoxidase (MPO) has been known to be a marker for the detection of neutrophil infiltration in intestinal inflammation (19) . The samples of colon were homogenized in 20 mM phosphate buffer (pH 7.4) for 30 sec and centrifuged at 15,000 x g for 20 min. The pellet was re-homogenized in 10 volumes of 50 mM potassium phosphate buffer (pH 6.0) containing 0.5% hexadecyltrimethyl ammonium bromide (HTAB, Sigma, St. Louis, MO) and 10 mM EDTA on an ice bath. The homogenate was then freeze-thawed once, sonicated for 1 min and centrifuged at 15,000 x g for 20 min. For the assay of myeloperoxidase activity, 50 μl of supernatants was added to the wells of a 96-well plate and mixed with 50 μl of 50 mM phosphate buffer (pH 6.0) containing 0.5% HTAB, 50 μl of o-dianisidine (0.68 mg/ml in distilled water), and 0.3 mM hydrogen peroxide to initiate the reaction. The complete reaction mixture was incubated for 3 min at 37˚C and the change in absorbance was measured spectrophotometrically at 450 nm. Pure human MPO (Sigma) was used as a standard. The inhibition percentage of MPO activity was calculated using the following equation:
A where A and B are the myeloperoxidase activity in DSSinduced colitis without or with the antibody treatment, respectively.
Chymase activity assay. The distal colon specimens were homogenized in 20 mM Na-phosphate buffer (pH 7.4) and then centrifuged at 15,000 x g for 30 min. The supernatant, which was rich in non-chymase proteases that would interfere with the assay, was discarded and the pellets were homogenized in 5 volumes (w/v) of 10 mM Na-phosphate buffer (pH 7.4) containing 2 M KCl and 0.1% polyoxyethylene octylphenyl ether, stored overnight at 4˚C, and then centrifuged at 15,000 x g for 30 min. The supernatants were used as the extract containing chymase (20) . The enzyme activities of chymase were determined using the substrate 0.2 mM N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (Sigma) containing 50 μg/ml heparin, 1 mg/ml bovine serum albumin, 1 mg/ml aprotinin, 2 M KCl and 100 mM Tris-HCl, pH 7.6 (21) . In all assays, 50 μl of sample was added to a total reaction volume of 200 μl in a 96-well plate. This substrate is hydrolyzed by chymase and continuously releases p-nitroaniline, which is a yellow chromophore. Thereby, multiple readings were taken and the reaction rates were measured by continuously monitoring the increase in absorbance at 405 nm for 5 min using a micro-ELISA reader. The gradient of linear increase of the absorbance (A405/min) was converted into protease activity. Protein concentration was measured using a bicinchoninic acid (BCA) protein assay reagent (Sigma) and the chymase activity was shown as the specific activity (mU/mg protein).
Western blot analysis. The distal colons (100 mg) were homogenized in 600 μl of lysis buffer (iNtRON Biotech, Korea), incubated for 30 min on ice, and centrifuged at 13,000 rpm for 5 min. The supernatants were transferred to a fresh tube and their protein concentrations were determined using a Pro-measure solution (iNtRON Biotech). Lysates (50 μg of protein) were separated by 10-15% SDS-PAGE and transferred to PVDF membranes (Amersham Pharmacia Biotech, Piscataway, NJ). After blocking with 5% skim milk, the membranes were blotted with the specific antibody Table I . Scoring of clinical signs for the disease activity index. ----------------------------------------------------------------------------------------------------- Disease activity index is the mean of individually combined scores of weight loss, diarrhea and bleeding.
- ----------------------------------------------------------------------------------------------------Figure 1 . Effect of anti-IgE antibody on weight loss (A) and colon length (B) in DSS-induced colitis. Colitis was induced by oral administration of DSS (5%) for 7 days and anti-IgE antibody (R35-92) was injected subcutaneously at two different doses, 5 μg/kg and 50 μg/kg body weight. IgG (50 μg/kg) and saline were used as comparative controls. The body weight of mice was measured every day during DSS treatment and colon length of mice was measured at day 7 after DSS treatment. Data are expressed as the mean ± SEM ( * p<0.05 vs. DSS plus saline).
against TNF-· and COX-2 for 12 h at 4˚C. After washing the membranes in 1X PBS containing 0.1% Tween-20, the immunoblots were incubated with the goat anti-mouse IgGhorseradish peroxidase (HRP) conjugate, at a 1:20,000 dilution for 45 min. Finally, the epitopes on the proteins recognized by the specific antibody were visualized using an enhanced chemiluminescence detection kit (Amersham Pharmacia Biotech).
Serum IgE measurements.
IgE levels in serum were measured using a commercial ELISA kit (Bethyl Laboratories, Montgomery, TX) according to the manufacturer's instructions. Briefly, microtiter plates were coated overnight at 4˚C with rat anti-mouse IgE diluted in phosphate-buffered saline (PBS) and then blocked with ELISA buffer containing 50 mM Tris-HCl (pH 7.2), 0.5% bovine serum albumin, 2 mM EDTA, 136.9 mM NaCl, 0.05% Tween-20 for 1 h at room temperature. Serum samples diluted in ELISA buffer were added to the plates and incubated overnight at 4˚C. After washing, the plates were incubated with 1 μg/ml second biotinylated antibody and streptavidin-peroxidase diluted in ELISA buffer for 1 h. Color development was performed with o-phenylene-diamine substrate (0.4 mg/ml) and 0.04% H 2 O 2 in PBS and the reactions were stopped by adding 4 M H 2 SO 4 . The optical density was measured at 492 nm using a microplate reader.
Statistical analysis. All values are described as the mean ± SEM. Statistical significance was determined using the Student's t-test to express the difference between the two groups. All p-values <0.05 were considered to reflect a statistically significant difference.
Results
Anti-IgE antibody inhibits the clinical signs in DSS-induced colitis.
We examined the inhibitory effects of non-anaphylactogenic anti-IgE antibody (R35-92) on the state of intestines in DSS-induced experimental colitis. Prior to DSS treatment of the mice, the anti-IgE antibody was subcutaneously injected only once at two doses, 5 μg/kg and 50 μg/kg body weight of the mice. IgG (50 μg/kg) and saline were injected as control by the same route. On day 7 after 5% DSS treatment, the physical signs (weight loss, colon length, diarrhea, and occult/gross bleeding) were observed separately and the DAI Figure 2 . Effect of anti-IgE antibody on DAI in DSS-induced colitis. Colitis was induced by oral administration of DSS (5%) for 7 days and anti-IgE antibody (R35-92) was injected subcutaneously at two different doses, 5 μg/kg and 50 μg/kg body weight. IgG (50 μg/kg) and saline were used as comparative controls. DAI was calculated at day 7 after DSS treatment as described in Materials and methods. Data are expressed as the mean ± SEM ( * p<0.05 vs. DSS plus saline). was calculated as shown in Table I . All mice treated with 5% DSS for 7 days survived and showed a significant loss of body weight (Fig. 1A ) and colon shortening (Fig. 1B) compared to the normal control group. In contrast, mice injected with anti-IgE antibody (both 5 μg/kg and 50 μg/kg) showed a significant attenuation of body weight loss and colon shortening caused by DSS treatment as assessed by body weight loss and colon shortening. In addition, the DAI was also remarkably inhibited in the groups injected with the anti-IgE antibody (5 μg/kg and 50 μg/kg) (Fig. 2) compared to the control groups injected with saline. Unexpectedly, control IgG administration slightly attenuated the DAI caused by DSS treatment.
Next, we observed the histological damage of the colon on day 7 after DSS treatment. Sections of distal colon tissue were stained by hematoxylin and eosin. As shown in Fig. 3B , DSS treatment revealed lesions of the colon consisting of multifocal areas, mucosal erosion, a loss of epithelial and goblet cells, the shortening and collapse of crypts, and submucosal edema. Administration of 5 μg/kg or 50 μg/kg of the anti-IgE antibody significantly reduced the lesions of the colon in DSS-induced colitis compared to that of saline or control IgG. Especially, the high concentration (50 μg/kg) of anti-IgE antibody remarkably showed protective and healing effects (Fig. 3) . These results indicate that non-anaphylactogenic anti-IgE antibody may effectively inhibit the development of colitis caused by DSS.
Anti-IgE antibody reduces myeloperoxidase (MPO) and chymase activity in DSS-induced colitis. MPO activity was
closely correlated with clinical, macroscopic, and histological grading of inflammation in the experimental groups. MPO activity was remarkably increased in the intestinal tissue of DSS-treated mice compared to that of normal control mice (19) . Administration of 5 and 50 μg/kg of anti-IgE antibody induced a 38% and a 54% decrease in MPO activity, respectively, in DSS-induced colitis, whereas the saline and control IgG groups exhibited no significant reduction in the development of DSS-induced colitis (Fig. 4A) . On the other hand, the increased chymase activity in the DDS-treated colon was also significantly reduced (Fig. 4B ) by anti-IgE antibody administration. These results strongly indicate that the recruitment of leukocytes, neutrophils and mast cells, could be reduced by a mechanism for the protective effects of anti-IgE antibody.
Anti-IgE antibody inhibits the expression of inflammation inducing factors in DSS-induced colitis.
IgE response plays an important role in the release of inflammatory mediators in helminth infections and allergic diseases (11, 14) . We thus examined the inhibitory effects of the anti-IgE antibody on the expression of TNF-· and COX-2, which are synthetic enzymes for prostagrandins, in UC tissue. The colon tissue was excised on day 7 after DSS treatment. TNF-· and COX-2 expression was detected by Western blot analysis using their specific antibodies. In the DSS-induced colitis model, the expression of TNF-· and COX-2 was increased in the intestinal tissue compared to that in the normal tissue. As the anti-IgE antibody was subcutaneously injected once on day 0, the increased expression of TNF-· and COX-2 was significantly reduced in the colon tissue, whereas both the saline and control IgG did not cause a remarkable decrease in their expression. Especially, the inhibitory effect of anti-IgE antibody was dependent on the injected dose (Fig. 5) . Next, Figure 4 . Effect of anti-IgE antibody on the activity of MPO (A) and chymase (B) in DSS-induced colitis. On day 0 of DSS treatment, anti-IgE antibody (R35-92) was injected subcutaneously at two different doses, 5 μg/ kg and 50 μg/kg body weight. IgG (50 μg/kg) and saline were used as comparative controls. The activities of MPO and chymase in the colon tissue were determined at day 7 after DSS treatment as described in Materials and methods. Data are expressed as the mean ± SEM ( * p<0.05 vs. DSS plus saline). Figure 5 . Effect of anti-IgE antibody on the expression of TNF-· and COX-2 in DSS-induced colitis. At day 0 of DSS treatment, anti-IgE antibody (R35-92) was injected subcutaneously at two different doses, 5 μg/kg and 50 μg/kg body weight. IgG (50 μg/kg) and saline were used as comparative controls. The analysis of TNF-· and COX-2 protein was performed on day 7 after DSS treatment as described in Materials and methods.
as the anti-IgE antibody (R35-92) has been known to prevent IgE synthesis and B cell activation through ligation of the IgE-IgE receptor (15, 16) , we determined the IgE levels in serum on day 4 after DSS treatment with and without antiIgE administration. DSS treatment slightly elevated the IgE level in serum (296±27 ng/ ml) compared to that (226±15 ng/ml) of normal mice. Thereafter, the injections of 5 and 50 μg/kg of the anti-IgE antibody resulted in an approximate 19% and 45% reduction of IgE levels in serum in DSS-treated mice, respectively, whereas the injection of control IgG induced no significant difference (Fig. 6) . These results implicate that the non-anaphylactogenic anti-IgE antibody (R35-92) may attenuate the manifestation of IgE-dependent colitis by blocking IgE-effector functions.
Discussion
In this study, we examined the effect of the nonanaphylactogenic anti-IgE antibody ameliorating all the considered inflammatory symptoms in a DSS-induced colitis murine model. The anti-IgE antibody significantly reduced most of the clinical signs, such as body weight loss, colon shortening, rectal bleeding, and diarrhea of colitis. Furthermore, the anti-IgE antibody significantly suppressed the activities of chymase and MPO and the expression of inflammatory markers such as TNF-· and COX-2.
Intestinal mast cells are thought to contribute to the mucosal inflammation in ulcerative colitis and Crohn's disease through release of inflammatory mediators. Mast cells are found within all layers of the gut wall throughout the gastrointestinal tract. Since mast cells are the major IgEeffector cells expressing a high affinity for IgE receptors FcεRI (22) , the activation of mast cells releases a number of biologically active substances to influence gut function, including fluid and electrolyte transport (23) (24) (25) . Thus, the evidence that mast cells may regulate gut function has been implicated in the pathogenesis of a number of gastrointestinal diseases including IBD, coeliac disease, food allergy, and systemic mastocytosis (26) . Several studies have shown that the number of mast cells was increased in IBD intestines (27, 28) and the enhanced levels of mast cell mediator were observed in the gut lumen of patients with active UC and CD (29, 30) . In addition, enhanced release of histamine and eicosanoids has also been described in actively inflamed IBD tissue after isolated intestinal mast cells were stimulated by crosslinking IgE receptors. The activation of isolated intestinal mast cells by crosslinking IgE receptors on the surface resulted in enhanced release of histamine and eicosanoids as well as a chloride secretory response (31) . In the present study, we also observed that the non-anaphylactogenic anti-IgE treatment could reduce the expression of mast cell-mediated inflammatory factors in DSS-induced colitis, indicating that the intestinal mast cell activation through FcεRI may play a role in the pathogenesis of UC.
High affinity IgE receptor, FcεRI, is expressed not only in mast cells and basophils but also in monocytes, Langerhans cells, eosinophils, neutrophils and platelets in humans (22, 32) , suggesting that the onset of colitis in humans is not only associated with mast cells but also with FcÁRI expressing cells. Evidence of the above has been documented in an animal study showing that the inflammatory signs in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced acute colitis were completely protected in FcεRI-deficient mice (33) and the release of IL-8 through the engagement of FcεRI in human neutrophils was inhibited by anti-IgE treatment (32) . Furthermore, FcεRI expression of eosinophils and macrophages may also contribute to the increased pathology by affecting the intestinal barrier. The absence of IL-4, which is a cytokine regulating the synthesis of IgE, also showed the inhibition of TNBS-induced colitis (34) . Collectively, these reports provide critical evidence that all FcεRI-expressing cells may play a role in the inflammation of colitis through an IgE-dependent activation mechanism, suggesting that the non-anaphylactogenic anti-IgE may extensively inhibit the interaction of IgE to all of the FcεRI-expressing cells as well as mast cells in the human intestine.
Unexpectedly, we observed that treatment of IgG used as a control could inhibit the development of DSS-induced colitis, even though its effect was lower than that of anti-IgE. Our results from a previous report showed that homologous IgG reduced the development of DSS-induced colitis via delivering its nonspecific inhibitory signaling by binding to their Fc receptors (FcÁR) (35) . FcÁRIIb, which is a low-affinity receptor for IgG, is expressed in various immune cells including B cells, T cells, mast cells, and macrophages. As FcÁRIIb has an immunoreceptor tyrosine-based inhibition motif (ITIM) in the intracytoplasmic domain, the engagement of FcÁRIIb with IgG negatively results in the regulation of cell activation, such as BCR-mediated B cell activation, TCR-mediated T cell activation, and FcεRI-mediated mast cell activation (36) . Thereby, IgG might provide the inhibitory signals in FcÁRIIb-expressing cells to downregulate IgE synthesis and release of mediators. Based on this hypothesis, the inhibitory effect of anti IgE in DSS-induced colitis might be due, not only to the blockage of IgE response, but also to the IgG ligation to FcÁRIIb.
So far, many processes in the inflammatory cascade, such as antigen presentation, T cell activation, overproduction of pro-inflammatory cytokines, and migration of inflammatory Figure 6 . Effect of anti-IgE antibody on IgE levels of serum in DSS-induced colitis. On day 0 of DSS treatment, anti-IgE antibody (R35-92) was injected subcutaneously at two different doses, 5 μg/kg and 50 μg/kg body weight. IgG (50 μg/kg) and saline were used as comparative controls. IgE levels of serum were determined on day 4 after DSS treatment as described in Materials and methods. Data are expressed as the mean ± SEM ( * p<0.05 vs. DSS plus saline). cells, were investigated as targets to treat IBD. In previous studies, TNF-· was a useful therapeutic target to blockade effector signals. The treatment of anti-TNF-· antibody inhibited the induction of many cytokines and adhesion molecules in chronic IBD (8) . However, the strategy of anti-TNF-· might be restricted to neutralize TNF-· released by activated cells, particularly mast cells, but not by other mediators, including tryptase, chymase, and histamine, in contrast with that of anti-IgE.
In conclusion, we observed that treatment with the antiIgE antibody may significantly reduce the clinical signs and the expression of inflammatory mediators in a colitis model caused by DSS treatment. These results suggest that the nonanaphylactogenic anti-IgE antibody may be a useful therapeutic agent for ulcerative colitis. However, anti-IgE therapy is limited to IgE-dependent responses only, even though the additional inhibitory effect might be derived from the engagement of FcÁRIIb on the surface of effector cells. Thus, the therapeutic agents for IgE-independent colitis remain to be studied.
